クリグルファーマ株式会社

Mission of Kringle Pharma

PHILOSOPHY

We will contribute to our society and global health by research, development and commercialization of innovative medicines for patients suffering from incurable diseases.

Business Activities

OUR BUSINESS

Research and development of HGF protein medicines

Target indications

  • Acute spinal cord injury
  • Amyotrophic lateral sclerosis
  • ALS Acute kidney injury
  • Vocal fold scar

NEWS

Apr 7, 2020Notice

Kringle Pharma additionally raises 740 million Japanese yen toward commercialization of recombinant human HGF drug.

PDF
Mar 2, 2020Notice

Kringle Pharma successfully raises 950 million Japanese yen to advance clinical development of recombinant human HGF.

PDF
Mar 2, 2020Notice

Kringle Pharma and Toho Holdings enter into a capital and business alliance for KP-100IT in acute spinal cord injury.

PDF
Dec 26, 2019AGM

New board members were selected at the 18th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.

Sep 23, 2019Notice

KP-100IT, recombinant human HGF for the treatment of acute spinal cord injury, was designated as an orphan drug in Japan as of September 12, 2019, with the approval of the Minister of Health, Labor and Welfare.

Jan 7, 2019Notice

Phase I/II study of recombinant human HGF, KP-100IT, for acute spinal cord injury was completed, and the clinical study report has been issued. The positive results of this study will be published later in a scientific journal and presented at academic conferences.

Jan 7, 2019Notice

Clinical data from Phase I study of recombinant human HGF, KP-100IT, for the treatment of ALS were published in Journal of Clinical Pharmacology (11 DEC 2018, DOI: 10.1002/jcph.1355). It was indicated that intrathecal administration of KP-100IT was safe and tolerable. Following the Phase I study, an investigator-initiated Phase II study is currently underway to confirm therapeutic efficacy of KP-100IT against ALS.

Dec 21, 2018AGM

New board members were selected at the 17th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.

Jul 31, 2018Notice

Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).

Jun 1, 2018Notice

Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website as follows. https://www.reprocell.com/

May 11, 2018Notice

Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

Feb 27, 2018Notice

A patent entitled ‘HGF preparation suitable for treatment of nervous diseases’ was granted in Japan. Patent No. JP6281992.

Jan 10, 2018Notice

Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.

Dec 22, 2017AGM

New board members were selected at the 16th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.

Dec 22, 2017Notice

Kringle Pharma announces completion of participant enrollment in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

PDF

Click here for news list